Adding multimedia: maia biotechnology's telomere-targeting agent thio, in combination with checkpoint inhibitor immune therapies atezolizumab (anti-pd-l1) or pembrolizumab (anti-pd-1), demonstrated significantly greater tumor inhibition

Chicago--(business wire)--maia biotechnology, inc. (nyse american: maia) announced today it intends to initiate its second phase 2 go-to-market trial evaluating thio, the world's first telomere-targeting agent, in patients with four cancer indications. the fda has awarded maia's lead anti-cancer agent thio two orphan drug designations, based on the preclinical efficacy data, for liver (hepatocellular carcinoma) and small cell lung cancer models.
MAIA Ratings Summary
MAIA Quant Ranking